1 Unlocking the power of the immune system to fight cancer and autoimmune disease Immutep Corporate Presentation August 2026 (ASX:IMM, NASDAQ:IMMP) 2 Forward Looking Statements The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889...
Immutep Corporate Presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from Immutep
- Immutep Quarterly Activities Report Q4 FY26
- Immutep Quarterly Activities Report and Appendix 4C
- Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
- Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor
- Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004
Later from Immutep
- Appendix 4E & 2026 Full Year Statutory Accounts
- S&P DJI Announces September 2026 Quarterly Rebalance
- Immutep Outlines Focused Development Strategy for Efti
- Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)
- Change to American Depositary Share Ratio
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep